By Dr Peter Baumgartner, Anaesthetist, West Leederville
The list of conditions that could benefit from Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RA) grows.
In June the Therapeutic Goods Administration (TGA) approved Tirzepatide as the first medical treatment for obstructive sleep apnoea (OSA). It has GLP-1 and glucose-dependent insulinotropic peptide activity (GIP).
The list of conditions that could benefit from Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RA) grows.
In June the Therapeutic Goods Administration (TGA) approved Tirzepatide as the first medical treatment for obstructive sleep apnoea (OSA). It has GLP-1 and glucose-dependent insulinotropic peptide activity (GIP).
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.